Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal SRIWIJAYA JOURNAL OF MEDICINE
Turnip, Laurens Frestasya A.
Unknown Affiliation
Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Computational Insights into the Dual Inhibition of PfATP6 and PfCRT by Bioactive Compounds from Spatholobus littoralis Hassk. Wahyuningtias, Dita Sheilla Putri; Putra, Oktavian Arya; Turnip, Laurens Frestasya A.; Ananda, Putu Desy Sagita; Wibowo, Syahputra; Wisynu Kusuma Wardhani, Bantari
Sriwijaya Journal of Medicine Vol. 8 No. 3 (2025): Vol 8, No 3, 2025
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/sjm.v8i3.362

Abstract

The current study examined the antimalarial activity of bioactive compounds extracted from Spatholobus littoralis Hassk. (bajakah wood) by an in-silico approach targeting the Plasmodium falciparum PfCRT and PfATP6 receptors. A total of forty-six phytochemicals were subjected to screening, resulting in the selection of six compounds based on bioactivity prediction, ADMET profiling, and molecular docking analyses.  Ramachandran plots were used to check the accuracy of the model, which showed that the protein structures were reliable.  Milbemycin A4-oxime exhibited the most significant binding affinity (−9.6 kcal/mol for PfCRT and −9.9 kcal/mol for PfATP6). These findings are comparable to or slightly better than those observed for artemisinin in this in silico model. These findings are preliminary and require further experiment. The molecule exhibited persistent interactions and favorable pharmacokinetic properties, indicating its potential use as a multitarget inhibitor.  Quercetin and 8-O-methylretusin had significant efficacy.  These results underscore the potential of S. littoralis metabolites, especially Milbemycin A4-oxime, as candidates for antimalarial drug development; however, additional in vitro and in vivo validation is necessary to establish efficacy and safety.
Co-Authors Ananda, Putu Desy Sagita Putra, Oktavian Arya Wahyuningtias, Dita Sheilla Putri Wibowo, Syahputra Wisynu Kusuma Wardhani, Bantari